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8-Methoxypsoralen (8-MOP) levels in the blood of vitiligo 
patients were determined through the use of a reverse-
phase high-performance liquid chromatographic method . 
The overall recovery of the internal standards was 85-94%, 
with the lower detection limit of 8-MOP at 2 ng. Peak 
blood levels as low as 130 ng/ml and as high as 3892 pg/ml 
w ere obtained in patients at 1-3 h following the oral admin-
istration of 0.6 mg/kg body weight of Oxsoralen capsules 
(Elder Pharmaceuticals Co.). These results are consistent 
with the clinical observation that maximum response in 
phototherapy .is obtained at about 2 h after oral adminis-
tration of the drug. Two hours after oral administration 
of 0.6 mg/ kg of Ox sora len , 8-MOP levels in the epidermis, 
P hotochemothera py, using either topical or oraI8-meth-oxypsoralen (S-MOP) and high-intensity long-wave UV radiation (PUV A) , has become a successful modality of treatment for vitiligo [1-7]. The method is more effective for treating pigmented individuals [S,9]. Over 
200 patients with vitiligo have been successfully treated at our 
Vitili go Center over the past 6-7 years. When a body surface area 
ofless than 20% is affected, 0.1 % solution of Ox sora len is applied 
topically, fo llowed by irradiation with gradually increasing doses 
of UV A. T he patients with over 20% surface involvement are 
treated w ith oral Oxsoralen capsules at a dosage of 0.6 mg/kg of 
body weight, followed by ex posure to gradually increasing dos-
ages of UV A. Approximately 60% of our patients respond to 
either topica l or oral therapy [S,9]. The question that we asked 
was why all patients fail to respond in a uniform fashion , even 
when the affected areas are of similar severity and duration'. We, 
therefore, developed a method to measure S-MOP in blood and 
tissue samples using a reverse-phase hi gh-performance liquid 
chromatographic (HPLC) method and measured blood S-MOP 
levels on a number of patien ts at timed intervals. 
Several authors [1 0-21] have reported methods for the deter-
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dermis, and whole skin of the guinea pig (in ng/g) were: 
epidermis, 330 ± 20; dermis, 89 ± 16; w hole skin, 379 ± 
19. Also detected were 8-MOP levels of 441 ± 22 ng/ml 
in aqueous humor, 166 ± 18 ng/ml in vitreous gel, 355 
± 15 ng/g in lens, and 410 ± 26 ng/g in retina. These 
results point to the fact that the eyes of the patient must 
be protected from exposure to sunlight after psoralen UV 
trea tment, and that 8-MOP is absorbed in blood unevenly 
and varies from patient to patient. The fact that only 50- 60% 
of the patients responded to psoralen photochemotherapy 
for vitiligo may be related to the variation of absorption 
of the drug in individual patients. J In vest D ennatol 
87:276-279, 1986 
mination of psoralens with various degrees of success. O ur lab-
oratory developed a method for the quantitative determination 
of S-MOP in plasma by using thin-layer chromatographic sep-
aration of the drug extracted fro m blood in a solvent mixture 
followed by scannin g flu orometric measurement on thin-layer 
plates [1 0]. For the present method we used a reverse-phase col-
umn and a solvent mixture containin g water and acetonitrile in 
order to obtain clear-cut sepa ration of S-MOP and trimethyl-
psoralen (TMP) fo r the quantitative measurement of each by using 
an HPLC m ethod [1 S]. 
SUBJECTS, MATERIALS, AND M ETHODS 
Patients Blood 8-MOP levels of 36 adult patients (20 males 
and 16 females) were determined after written informed consents 
were obtained. Ten-milliliter blood sa mples were drawn prior to 
oral administration of 0.6 m g/kg body weight of Oxsoralen cap-
sules. After drug ingestion blood samples were drawn at hourly 
intervals up to 4 h and at 24 h. All patients involved in this stud y 
fasted overnight prior to the morning of medication and drawing 
of blood sa m pIes. 
Animals Guinea pigs were used as an animal model in this study 
for photobiologic experiments. In addition, the guinea pig was 
used for measuremen ts ofS-MOP in whole skin , epidermis, der-
mis, ophthalmic fluid s, lens, and retina 2 h after oral administra-
tion of8-MOP (0. 6 m g/kg of body weight) in corn oil. H air was 
removed from the white areas of spotted guinea pigs and the areas 
were marked into 2-cm squares. Each square was used for ap-
plication of 0. 1 ml of 0.1% S-MOP, 0. 1 ml of propylene glycol-
ethanol mixture (as a blank), and 0. 1 ml of the material extracted 
from blood of patients obtained 2 h after the dru g administration . 
All topica l applica tions were made in triplicate. Thirty minutes 
after application , the animals were exposed to a high-intensity 
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(UV A) source (Psoralite, Elder Pharmaceuticals Co.). The total 
dose applied was 1.2J/cm 2 . Phototoxic responses were observed 
at 24, 4S, and 72 h . 
Materials Crystalline S-methoxypsoralen and trimethylpsora-
len were o btai ned from Sigma C hemical Co., St. Louis, Missouri . 
O xsoralen ca p sules and 1 % Oxsoralen lotio n were obtained from 
Elder Pharmaceutica ls, Bryan , Ohio. A cetonitrile, HPLC grade 
and all other anal y tical-g rade solvents and chemica ls were ob-
tained from Fisher Scientific Co., Silver Spring, M aryland . 
Assay For extractio n o fS-MOP from blood , fluids , and tissu e 
homogenates, a 2.0-ml aliquot (or less for ophthalmic fluids) was 
mixed with 5.0 ml of 0 .05 M ace tate buffer, pH 3.5 in a 50-ml 
stopp ered Pyrex tube. Sixteen millilite rs of eth yl e ther were added 
at room temperature and tubes were capped . The mi x ture was 
shaken on a reciprocating shaker for 10 min under a hood at 
70-S0 s trokes/min . After centrifugation for 10 min at 1020 g, 10 
ml of organic layer were transferred to a scintillation vial and the 
solvent was eva porated to dryness under a stream of dry nit rogen 
gas. Prior to HPLC analysis , the dry residue was reconstituted 
in 50 J.LI of a bso lute ethanol , and 10 J.LI were injected on the 
chromatographic co lumn. For the meas urem ents ofS-MOP levels 
in tissues, these were homogenized in 0.05 M acetate buffer (pH 
3.5) and the drug was extracted as described above. The ophthalmic 
fluids were treated like blood for extraction and the m easurem ents 
ofS-MOP. 
Chromatographic Parameters The instrument used was a 
Varian (model 5000) high-pressure liquid chro m atograph , equipped 
w ith a 254- 2S0 nm UV detector , operated at 254 nm, with a 10-
J.LI loop inj ector. The analytical column was a prepacked 30 cm 
x 4 mm Varian Micropack (MCH-l0), containing R everse Phase 
V ydac. The mobile phase consisted of a mixture of wa ter and 
acetonitrile. The fl ow rate was 2 .0 ml/min and the detector sen-
sitivity was set at 0.16 AU, while the chart speed on the l-mV 
Varian recorder (model 9176) was 1 cm / min . 
Analytical Standards and Preparation of Calibration 
Curves A stock solution ofS-MOP was prepared by dissol ving 
100 mg of analytical grade crystalline S-MOP in 10 ml of absolute 
e thanol. Suitable dilution of this s tandard, having S- MOP con-
centration of 1 m g/ml , was also prepared in absolute ethanol. A 
series of further dilutions was m ade from the latter , so that 10 J.LI 
(injected into the column) contained 2, 5, 10, 15, and 20 ng of 
S-MOP. For recovery studies, enough S-MOP was added to 2.0 
ml of blood sa mples so that the final concentrations in blood were 
2, 5 , 10, 20, and 30 ng/ ml. The drug w as then extracted from 
each sample as outlined in the assay method . 
RESULTS 
The re ten tion time for S-MOP was S.O min which, with the 
retention time of 16.5 min for the TMP, was used as an internal 
standard . Table I shows the relationship between the peak heights 
in cm and the amounts ofS-MOP (in ng ) inj ec ted onto the c11ro-
Table I. Relationship Between th e Amounts of 
S-M ethoxypso ralen (S-MOP) Inj ected onto the 
High-Performan ce Liquid C hrom atog raphic Column and the 
Pea k H eig hts 
8-MO P Injected (ng) 
2.0 
5.0 
10.0 
15. 0 
20.0 
Peak Height (cm) 
0.96 :!: 0.2 
2.64 :!: 0.6 
5.85 :!: 1.2 
8.88 :!: 1. 5 
11. 90 :!: 2.6 
8-MOP (2.0,5.0, 10.0, 15.0, and 20.0 ng) was injected onto the chromatographic 
column and the corresponding eluted peak heights of the drug were recorded. For 
de[ails, sec Sl/bjeas, Mat erials alld Methods. Each point is an average of 7 determi-
na eions. 
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Table II. Time Course of S-Methoxypsoralen (S-MOP) 
Recovery from Blood of 20 M ale Subjects (ng/ ml) 
Age Hour 2 Hours 3 Hours 4 Hours 24 Hours 
32 516 870 480 226 0 
36 782 642 662 182 56 
28 85 101 130 95 35 
45 3730 3892 490 107 0 
39 309 3357 385 59 0 
35 392 336 230 108 25 
27 357 336 225 116 0 
46 288 398 480 216 0 
46 423 468 395 320 0 
23 558 880 656 lI S 0 
29 468 566 289 198 20 
48 1390 2508 337 166 12 
52 1087 1567 358 172 50 
33 480 996 467 152 36 
36 395 677 520 11 8 22 
35 287 755 396 129 0 
25 348 589 288 206 0 
24 225 360 160 215 15 
30 290 498 237 200 18 
32 310 470 260 196 0 
Ten milliliters of blood were drawn from each subject in heparinized tube prior 
to oral administration of 0.6 mg/kg OxsoraIcn capsules. After the drug intake, 10 
ml of blood were drawn at hourly interva ls up to 4 h and then at 24 h. Extraction 
and analys is of 8-MOP is described in Sl/bjects, Materials, alld Methods. Each resu lt 
was obtained by averaging duplica te assays. All predrug blood samples were neg-
J[lVC. 
matographic column. Each point was es tablished from an average 
of7 determinations. As seen in Table I, a fa irl y linear relationship 
was obtained from external standard solutions . 
The amounts of S- MOP added to and recovered from blood 
varied from S3-95%. When 5 .0 n g were added , per ml of blood , 
4.15 ± 0.6 ng (83%) were recovered . Similarly , for 10.0 ng, 15 .0 
ng, and 20.0 ng S-MOP added per ml of blood , the respective 
recoveries were 9. 10 ± 0.5 (91%),14.25 ± 0.9 (95%), and 17.20 
± 2.0 (S6%) . 
Blood S- MOP levels were determin ed at different times after 
oral administratio n (of 0.6 m g/kg body weight of the drug) and 
the res ults in male subjects are presented in Table II. The cor-
responding values for female patients are presented in Table III. 
As can be seen, wide variations of blood S-MOP levels were 
Table III. Time Course of S-Methoxypsoralen (S-MOP) 
Recovery from Blood of 16 Female Subjects (ng/ ml) 
Age I Hour 2 Hours 3 HOllrs 4 Hours 24 Hours 
50 120 330 520 128 62 
38 126 298 452 155 56 
29 238 393 498 230 26 
23 305 446 338 280 11 5 
40 338 609 556 235 12 
47 414 659 388 166 0 
25 512 738 439 208 0 
46 250 586 452 333 123 
48 382 296 487 400 68 
52 250 380 406 239 59 
26 633 121 7 830 236 36 
30 136 288 493 11 5 0 
35 322 659 652 219 0 
28 423 1360 666 189 0 
38 325 296 460 299 20 
55 369 455 380 154 16 
Ten milliliters of blood were drawn from each subject in heparinized tube prior 
to oral administration of 0.6 mg/kg Oxsoralen capsules. After the drug intake, 10 
ml of blood were drawn at hourly intervals up to 4 h and then at 24 h. Extraction 
and analysis of 8-MOP is described in S"bjcas, Mate,.ials, alld Methods. Each result 
was obtained by averaging duplicate assays. All predrug blood samples were neg-
ative . 
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Table IV. 8-Methoxypsoralen (8-MOP) Levels in Skin and 
Eye Tissues and in Ophthalmic Fluids of the Guinea Pig Two 
Hours After Oral Administration of 0.6 mg/kg of the Drug 
Tissue or Fluid 
Whole skin 
Epidermis 
Dermis 
Retina 
Lens 
Aqueous humor 
Vitreous ·gel 
8-MOP Recovered (ng/ml or ng/g)" 
379 ± 19 
330 ± 20 
89 ± 16 
410 ± 26 
355 ± 15 
441 ± 22 
166 ± 18 
"Results rep resent an average of 6 determinations. Ophthalmic tissues and fluids 
were pooled from 4 animals for each determination. 
observed. However, the results indicate that peak blood 8-MOP 
levels occurred most often at 2 h after ingestion of the drug, 
except for a few cases . One of the 20 male patients absorbed the 
drug rather poorly (patient 3); 6 of the 20 male patients obtained 
peak 8-MOP levels of over 800 ng/ ml, and 2 of the 6 patients 
reached peak levels of over 3000 ng/ml. In addition, 2 of the male 
patients obtained blood psora len levels of 1500-2500 ng/ml. The 
peak blood levels of the other male patients were between 755 
and 336 ng/ml. Table III shows that 7 of the 16 female patients 
obtained peak blood levels at 3 h, although 8-MOP levels at 2 h 
were sufficiently high in these patients. Two of the 16 female 
patients obtained peak 8-MOP blood levels of over 1000 ng/ml 
and 14 of 16 female patients obtained peak 8-MOP levels of 
406-738 ng/ml. 
Presented in Table IV are the 8-MOP levels in eye tissues, 
ophthalmic fluids, and skin tissues determined 2 h after oral 
administration (0.6 mg/kg) to the guinea pigs. Aqueous humor 
was drawn from the anterior chamber of the eyes with a tuberculin 
syringe. Vitreous gel, retina, and lens were dissected out. The 
extraction and determination of 8-MOP in these fluids were per-
formed by the same assay method as for blood . The drug levels 
m retma, lens , aqueous humor, skin, and epidermis were higher 
as compared with the level in the dermis . The concentration in 
aqueous hun:or, lens, and retina was more than twice as high 
compared With that in vitreous gel. Similarly, the level in epi-
dermiS was more than 3 times higher than that of the dermal level 
of the drug. 
In order to determine whether the compound, extracted from 
the blood and measured by HPLC, was photobiologically active, 
experiments were conducted using the guinea pig as the test an-
imal. The material extracted from patients' blood was pooled, 
evaporated to dryness, and reconstituted in 0.5 ml of a mixture 
of 30% propylene glycol, 69% ethanol, and 1 % acetone; 0.1 ml 
of the solvent, as well as the extracted material and 0.1 % solutions 
of 8-MOP and TMP were applied in triplicate on 2-cm squares 
of marked skin surfaces 30 min prior to exposure to 1.0 J/cm2 
UV A. Phototoxic responses were noted at 24, 48 , and 72 h . The 
results were 1 + response at 24 h; 2 + response at 48 h, and 
between 2 + and 3 + response at 72 h for the extracted material 
from blood as well as for standard 8-MOP and TMP (1 + = 
erythema, 2 + = erythema plus edema, and 3 + = erythema, 
edema, and vesiculation). 
The methods used to help with the tentative identification of 
the compound extracted from blood were thin-layer chromatog-
raphy' and cochromatography with authentic 8-MOP on thin-
layer plates in 2 separate solvents (900: 10 benzene-ethyl acetate 
by vol and ethylacetate : chloroform: acetone: methanol: acetic acid, 
5: 5: 3: 1 : 1 by vol), as well as by gas-chromatography and mass 
spectrometric fragmentation pattern. By gas-chromatography, 
the material from the blood was eluted at an identical position as 
authentic 8-MOP. The mass spectral fragmentation of the ex-
tracted material was also identical to that of authentic 8-MOP 
producing masses at 216, 188, 173 dalton, etc., by elimination of 
- co, CH3, etc. 
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DISCUSSION 
By using thin-layer chromatography and scanning fluorometr 
we reported plasma 8-MOP level of a patient. The peak level It 
2 h was 3000 ng/ml [10). A large number of investigators, us in 
a variety of methods, reported 8-MOP levels in psoriatric patient~ 
and normal volunteers [11-21). The peak blood or plasma 8-MOP 
levels reported varied widely from as low as 2 ng/ml to as high 
as 3000 ng/ml [10-28) . Our results, as presented here, are gen-
erally higher than tho~e reported elsewhere. In general, there was 
no clear-cut relatIOnship between peak plasma levels, time at which 
the p<:ak leve~s occurred, the UV A exposure time, and the ther-
apeutic effectiveness. Ideally, patients should receive UV A treat-
ment when epidermal 8-MOP level is highest . This time may be 
slightly later than the time at which peak blood level is achieved 
Murata et al [29) studied distribution of [3H)TMP in the ra~ 
and found that 2 h after oral administration the drug level was 
of the order of 4.0 J.Lg/ml. Also, we reported significant TMP 
accumulatIOn m the whole skin and epidermis of the guinea pig 
[18) . We find now that accumulation of 8-MOP is also high 
(r.esults III Table IV) 111 th<: whole skin and epidermis of the guinea 
pig after oral ad!mmstratlon of the drug with a dose comparable. 
to a dose III patients treated for therapeutic effectiveness. 
. .A number of reports (30-38) indicate that photochemotherapy 
lllitiates cataract formation . Lerman and Borkman [33) demon-
strated accumulation of 8-methoxypsoralen in the ocular lens of 
the rat. We also reported significant accumulation of TMP in 
ocul~r flUids of the guinea pig [18). Results in Table IV show 
slgmficant ~ccumulation of 8-MOP in retina, lens, aqueous hu-
mor, and vitreous gel of the guinea pig . These results are similar 
to those reported by Pathak et al [3) and Stern et al [38), and 
pomt to the fact that the eyes of the patient must be protected 
from exposure to additional sunlight after psoralen UV treat-
ment [34-37) . 
In summary, a reverse-phase HPLC method for measurements 
of 8-MOP in blood, ophthalmic fluids, retina, lens, skin, epi-
d.e~mls, and dermiS has been developed. The lower limit of sen-
Sitivity of the metho~ is of th~ order of 2 ng/ml. 8-Methoxy_ 
~soralen IS preferentially localized 111 certa111 body fluids and 
tissues, such as aqueous humor and epidermis . Since aqueous 
humor, lens, and ophthalmic tissues acquire very high concen-
tratIOns of psoralens for 24 h, protection of the eyes during pho-
totherapy and prevention of exposure to the sunlight for 24 h are 
extremely important for prevention of blindness . 
Since our results appear to be higher than those reported else-
where, we believe that the reverse-phase HPLC method is more 
sensitive and would be more useful in correlating clinical re-
sponses 111 the photochemotherapy of skin diseases with blood 
levels of 8-MOP. 
It also becomes necessary to determine blood psoralen levels 
of 40% nonresponding patients at timed intervals to determine 
whether the drug is absorbed sufficiently and at what time after 
or~1 administration. In case of poor blood 8-MOP levels, expected 
Skll~ levels may also be very low and, hence, little or no photo-
toxIcity or melanogenesIs will occur. In slIch instances a better 
method of drug delivery at the target organ must be designed for 
the nonresponders. 
The allthors are il/debted to Ms. Theresa Drydell for editorial assistal/ce. 
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